Precision BioSciences (DTIL) Stock Overview
A clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
DTIL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Precision BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.67 |
| 52 Week High | US$8.82 |
| 52 Week Low | US$3.53 |
| Beta | 1.09 |
| 1 Month Change | 17.64% |
| 3 Month Change | 64.29% |
| 1 Year Change | 51.59% |
| 3 Year Change | -73.69% |
| 5 Year Change | -97.46% |
| Change since IPO | -98.73% |
Recent News & Updates
Recent updates
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026
Dec 29Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts
Aug 06
It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks
Jun 23Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?
Mar 14Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?
Dec 08Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles
Sep 02Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash
Aug 16Precision BioSciences Q2 2022 Earnings Preview
Aug 05Precision Bio: Another CAR-T Laggard With No Solid Prospects
May 09Shareholder Returns
| DTIL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.6% | -0.1% | 3.4% |
| 1Y | 51.6% | 40.2% | 28.4% |
Return vs Industry: DTIL exceeded the US Biotechs industry which returned 40.2% over the past year.
Return vs Market: DTIL exceeded the US Market which returned 28.4% over the past year.
Price Volatility
| DTIL volatility | |
|---|---|
| DTIL Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: DTIL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DTIL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 68 | Michael Amoroso | precisionbiosciences.com |
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy.
Precision BioSciences, Inc. Fundamentals Summary
| DTIL fundamental statistics | |
|---|---|
| Market cap | US$172.11m |
| Earnings (TTM) | -US$46.61m |
| Revenue (TTM) | US$34.26m |
Is DTIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DTIL income statement (TTM) | |
|---|---|
| Revenue | US$34.26m |
| Cost of Revenue | US$0 |
| Gross Profit | US$34.26m |
| Other Expenses | US$80.87m |
| Earnings | -US$46.61m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.81 |
| Gross Margin | 100.00% |
| Net Profit Margin | -136.03% |
| Debt/Equity Ratio | 24.3% |
How did DTIL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/12 06:27 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Precision BioSciences, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Debjit Chattopadhyay | Guggenheim Securities, LLC |
| Debjit Chattopadhyay | H.C. Wainwright & Co. |
| Patrick Trucchio | H.C. Wainwright & Co. |